Thrombomodulin Inhibits Tissue factor Mediated Thrombin Generation in blood and Prothrombin Complex Concentrates

A recombinant thrombomodulin (Recomodulin, Asahai Kasei, Tokyo, Japan) is currently used for the management of DIC and related disorders. Beside inhibiting thrombin and forming complexes with this enzyme, Recomodulin (RM) mediates its therapeutic effects involving modulation of inflammatory processes and thrombogenesis. The purpose of this study is to determine the effect of RM on thrombin generation in plasma and prothrombin complex concentrates. RM (2.02 mg/ampule) was commercially obtained. Working solutions of buffered RM were prepared at 100ug/ml. Tissue factor mediated generation of thrombin and its inhibition in normal human plasma (NHP) (n=25), platelet rich plasma (PRP) (n=25) and various prothrombin complex concentrates such as Beriplex, Cofact, Feiba, Konyne, Octaplex, Preconativ, Profilnin, Prothromplex ( 1u/ml) were investigated utilizing a fluorometric thrombokinetics method. The effect of RM on thrombin mediated fibrinokinetics was also measured using an optical method. RM produced a concen...